# Viking Therapeutics, Inc (VKTX) stock analysis and sentiment Canonical page: https://synoptiv.com/stock/VKTX Methodology: https://synoptiv.com/methodology Author: Synoptiv Research Engine Last analyzed: Sep 11, 2026 Viking Therapeutics, Inc (VKTX) last closed at $32.13, around the middle of its 52-week range of $22.96–$43.15. Composite market sentiment across 1 analysis is positive (+15 on a −100 to +100 scale), as of Sep 11, 2026. ## What the data says At $32.13, Viking Therapeutics sits roughly in the middle of a wide 52-week band that runs from $22.96 to $43.15. The stock is about 26 percent below the high end of that range and roughly 40 percent above the low, and a range that spans nearly a two-fold difference between its extremes describes a name that has moved a great deal over the past year rather than settling into a narrow channel. Beta of 0.68 adds a wrinkle to that picture: the shares have historically moved less than one-for-one with the broader market, meaning much of the travel within that range has come from company- and sector-specific developments rather than from general market direction. The valuation figures reflect a business without earnings. Forward P/E is negative at roughly -7.4, which is what happens when analysts expect continued losses rather than profits, and profit margin is reported at zero — consistent with a clinical-stage company that has no approved product generating revenue. That leaves price-to-book, at about 9.2 times, as the more meaningful anchor, and a market capitalization near $3.7 billion that rests on the expected value of the pipeline rather than on current financial results. In practical terms, the market is pricing future outcomes, not a current earnings stream, so conventional earnings-based measures carry little information here. Recent coverage splits between the company itself and the obesity-drug field it sits in. Company-specific items address its cash position of $502 million and a remaining 2026 catalyst, a July decline in the shares, a day of outperformance versus the broader market, and disagreement among commentators about analyst price expectations. The wider-sector items place Viking alongside larger players — Novo Nordisk's pediatric obesity results for semaglutide, comparisons with Eli Lilly, and speculation about acquisition activity following Vertex's $10 billion purchase of Crinetics. The overall flow is heavier on positioning within the GLP-1 landscape and on commentary than on new clinical data from the company. ## About Viking Therapeutics, Inc Viking Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Incorporated in 2012, it develops small-molecule therapies for metabolic and endocrine disorders, with a portfolio centered on receptor-selective compounds in both oral and injectable forms. As a clinical-stage company, it does not yet have an approved product. Its most advanced program is VK2735, a dual agonist of the GLP-1 and GIP receptors under study for obesity and related metabolic conditions in both subcutaneous and oral formulations. The company is also developing VK2809, a selective agonist of thyroid hormone receptor beta evaluated in metabolic dysfunction-associated steatohepatitis (previously termed NASH), and VK0214, a thyroid hormone receptor beta agonist studied in X-linked adrenoleukodystrophy. Earlier candidates include VK5211, a non-steroidal selective androgen receptor modulator, and VK0612, an oral candidate in metabolic disease. ## Company profile - Symbol: VKTX - Exchange: NASDAQ - Security type: Stock - Sector: Healthcare - Industry: Biotechnology - Composite sentiment: positive (15 on a -100 to +100 scale) ## Key statistics | Metric | Value | | --- | ---: | | Market capitalization | $3.74B | | Enterprise value | $3.25B | | Forward P/E | -7.42 | | Price to book | 9.16 | | Beta | 0.68 | | Net margin | 0.00% | | 52-week high | $43.15 | | 52-week low | $22.96 | | Average volume | 2.21M | ## Related stocks - [CELC](https://synoptiv.com/stock/CELC) - [RLAY](https://synoptiv.com/stock/RLAY) - [TNGX](https://synoptiv.com/stock/TNGX) - [IOVA](https://synoptiv.com/stock/IOVA) - [LEGN](https://synoptiv.com/stock/LEGN) - [IDYA](https://synoptiv.com/stock/IDYA) - [GRAL](https://synoptiv.com/stock/GRAL) - [DNLI](https://synoptiv.com/stock/DNLI) - 950160.KQ ## Recent news - [Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?](https://finance.yahoo.com/markets/stocks/articles/worth-investing-viking-therapeutics-vktx-133003862.html) — Sep 11, 2026 - [Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors](https://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-inc-vktx-declines-214506122.html) — Sep 10, 2026 - [Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?](https://www.fool.com/coverage/better-buy/2026/09/10/axsome-therapeutics-vs-viking-therapeutics-which-healthcare-stock-is-a-better-buy-in-2026/) — Sep 10, 2026 - [Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.](https://www.fool.com/investing/2026/09/10/analysts-have-a-92-target-on-viking-therapeutics-h/) — Sep 10, 2026 - [Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know](https://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-inc-vktx-sees-215006686.html) — Sep 9, 2026 - [Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study](https://www.zacks.com/stock/news/2986260/novo-nordisk-s-semaglutide-meets-goal-in-pediatric-obesity-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2986260) — Sep 8, 2026 - [Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.](https://www.fool.com/investing/2026/09/05/viking-therapeutics-trades-well-below-its-wall-str/) — Sep 6, 2026 - [Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run?](https://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-vktx-stock-fully-201010043.html) — Sep 4, 2026 - [Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?](https://finance.yahoo.com/markets/stocks/articles/why-mirum-pharmaceuticals-mirm-6-153015722.html) — Sep 4, 2026 - [Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know](https://www.zacks.com/stock/news/2984801/viking-therapeutics-inc-vktx-outperforms-broader-market-what-you-need-to-know?cid=CS-ZC-FT-fundamental_analysis|yseop_template_6-2984801) — Sep 3, 2026 ## Frequently asked questions ### What is the current market sentiment for VKTX? As of Sep 11, 2026, Viking Therapeutics, Inc (VKTX) carries positive (+15 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report. ### How has VKTX stock been performing? Viking Therapeutics, Inc last closed at $32.13, around the middle of its 52-week range of $22.96–$43.15. ### What is VKTX's market cap and valuation? Viking Therapeutics, Inc has a market capitalization of about $3.74B. ### What sector is VKTX in, and who are its competitors? Viking Therapeutics, Inc operates in the Healthcare sector, specifically Biotechnology. Comparable companies include CELC, RLAY, TNGX, IOVA, LEGN. ### Where can I find a full analysis of VKTX? The full VKTX report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account. ## Important information This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice. - [Methodology](https://synoptiv.com/methodology) - [Disclosures](https://synoptiv.com/disclosures) - [Full report](https://synoptiv.com/stock/VKTX/v/1) (account and access required)